Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FPRX

Five Prime Therapeutics (FPRX) Stock Price, News & Analysis

Five Prime Therapeutics logo

About Five Prime Therapeutics Stock (NASDAQ:FPRX)

Key Stats

Today's Range
$38.00
$38.00
50-Day Range
$37.65
$38.00
52-Week Range
$2.61
$38.90
Volume
N/A
Average Volume
1.98 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Receive FPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Five Prime Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FPRX Stock News Headlines

CMMB Chemomab Therapeutics Ltd.
“This Changes Everything” - Trump Hands Millions Massive IRS Gift
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
What Is The Prime Rate Today?
See More Headlines

FPRX Stock Analysis - Frequently Asked Questions

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its quarterly earnings results on Friday, November, 6th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.14. The biotechnology company had revenue of $2.05 million for the quarter, compared to analysts' expectations of $3.50 million. Five Prime Therapeutics had a negative trailing twelve-month return on equity of 75.84% and a negative net margin of 554.71%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Five Prime Therapeutics investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), OPKO Health (OPK), Pfizer (PFE), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/06/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FPRX
Fax
N/A
Employees
87
Year Founded
N/A

Profitability

Net Income
$-137,200,000.00
Net Margins
-554.71%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.87 million
Book Value
$4.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.77 billion
Optionable
Optionable
Beta
4.40
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:FPRX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners